Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection

被引：0
作者：
Fabio Natale
Bianca Bizzarri
Veronica Cardi
Aurelia Gaeta
Paola Villani
Giuseppina Liuzzi
Mario De Curtis
机构：
[1] “La Sapienza” University of Rome,Department of Pediatrics and Child Neuropsychiatry
[2] “La Sapienza” University of Rome,Laboratory of Virology, Department of Public Health and Infectious Diseases
[3] IRCCS Policlinico S. Matteo,Department of Pharmacology
[4] I.N.M.I. Lazzaro Spallanzani,Neonatal Intensive Care Unit, Department of Pediatrics and Child Neuropsychiatry
[5] “Sapienza” University of Rome,undefined
来源：
Italian Journal of Pediatrics | / 41卷
关键词：
Valganciclovir; Ganciclovir; Cytomegalovirus; Cerebrospinal fluid; Congenital infection;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Currently, there is no evidence whether ganciclovir, or its oral prodrug valganciclovir, penetrates into the cerebrospinal fluid of human infants treated for congenital cytomegalovirus infection. Here, we report a case study providing evidence that ganciclovir, administered as valganciclovir, reaches the infant’s cerebrospinal fluid when used at the currently recommended dose for congenital cytomegalovirus infection.
引用
收藏
相关论文
共 60 条
[1]  
Kimberlin DW(2003)Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial J Pediatr 143 16-25
[2]  
Lin CY(2009)Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system J Clin Virol 46 S22-6
[3]  
Sánchez PJ(2013)Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection Curr Drug Metab 14 208-15
[4]  
Demmler GJ(2008)Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease J Infect Dis 197 836-45
[5]  
Dankner W(2010)Penetration of drugs through the blood-cerebrospinal fluid/blood–brain barrier for treatment of central nervous system infections Clin Microbiol Rev 23 858-83
[6]  
Shelton M(2013)A case of severe ganciclovir-induced encephalopathy Case Rep Neurol 5 183-6
[7]  
Oliver SE(2006)Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring Ann Pharmacother 40 143-6
[8]  
Cloud GA(1986)Human pharmacokinetics of the antiviral drug DHPG Clin Pharmacol Ther 40 281-6
[9]  
Sánchez PJ(1999)A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum J Pharm Biomed Anal 21 657-67
[10]  
Demmler GJ(2001)Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94 Clin Diagn Lab Immunol 8 1279-81
123456